External quality assessment samples of thromboelastography test reagents and their preparation method and application
By providing inter-ventricular quality evaluation samples and preparation methods for thromboelastography experimental reagents, the problem that the thromboelastography instrument cannot effectively evaluate the quality of the reagents is solved, and the stability and reliability of the thromboelastography experimental results are achieved.
Patent Information
- Application Number
- CN202111676324.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-31
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-12-31
AI Technical Summary
The existing thromboelastography instruments cannot effectively evaluate and control the quality of reagents in thromboelastography experiments, which affects the accuracy and reliability of experimental results.
Provide inter-chamber quality evaluation samples of thromboelastography experimental reagents and their preparation methods, including quality control samples of the kaolin group, rapid kaolin group, heparinase group, fibrinogen group and platelet inhibitor group, through these samples, from multiple Dimensionally evaluate the quality of reagents to ensure the stability and reliability of experimental results.
Through multi-dimensional evaluation, the quality of the thromboelastic map experimental reagent is ensured, the accuracy and reliability of the experimental results are improved, and the effectiveness of the thromboelastic map experiment is ensured.
Smart Images

Figure CN114295821B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of biomedical technology, and in particular to an inter-laboratory quality assessment sample of a thromboelastogram test reagent and a preparation method and application thereof. Background Art
[0002] Thromboelastograph is an analyzer that monitors the human coagulation process from the entire dynamic process of fibrinogen and platelet aggregation, coagulation, fibrinolysis, etc. Through the thromboelastograph, a thromboelastogram can be obtained, and thus the patient's blood sample conditions, such as clot formation time, clot strength, and fibrinolysis rate, can be obtained. With the continuous development of the application of thromboelastograph in biomedical fields such as disease prevention, diagnosis, and treatment, the quality control of thromboelastograph has become particularly important. At present, there are inter-laboratory quality assessment samples for thromboelastographs, but they can only achieve quality control of the instrument, and cannot evaluate and control the quality of reagents in thromboelastograph experiments. Summary of the invention
[0003] To solve the above problems, the present application provides an inter-laboratory quality assessment sample of thromboelastometry test reagents, a preparation method and an application thereof, and provides an inter-laboratory quality assessment sample for reagents in thromboelastometry experiments to ensure the quality of reagents in thromboelastometry experiments, thereby ensuring the accuracy and reliability of thromboelastometry test results.
[0004] In the first aspect, the present application provides an inter-laboratory quality assessment sample of a thromboelastogram test reagent, wherein the inter-laboratory quality assessment sample includes at least one of a kaolin group, a rapid kaolin group, a heparinase group, a fibrinogen group, and a platelet inhibitor group; the kaolin group includes a first high coagulation quality control sample, a first normal quality control sample, and a first low coagulation quality control sample, wherein the R value of the first high coagulation quality control sample is less than 4min and the MA value is greater than 65mm, the R value of the first normal quality control sample is 4min-7min and the MA value is 45mm-65mm, and the R value of the first low coagulation quality control sample is less than 4min and the MA value is greater than 65mm. The rapid kaolin group includes a second high coagulation quality control sample, a second normal quality control sample, and a second low coagulation quality control sample, the ACT value of the second high coagulation quality control sample is less than 86s and the MA value is greater than 65mm, the ACT value of the second normal quality control sample is 86s-118s and the MA value is 45mm-65mm, and the ACT value of the second low coagulation quality control sample is greater than 118s and the MA value is less than 45mm; the heparinase group includes a third normal quality control sample and a first abnormal quality control sample, and the R 普通杯 With R 肝素酶杯 The difference between the values of the first abnormal quality control sample is less than or equal to 2min. 普通杯 With R 肝素酶杯The difference is greater than 2min; the fibrinogen group includes a first high-value quality control sample, a fourth normal quality control sample, and a second abnormal quality control sample, the MA value of the first high-value quality control sample is greater than 24mm, the MA value of the fourth normal quality control sample is 11mm-24mm, and the MA value of the second abnormal quality control sample is less than 11mm; the platelet inhibitor group includes a fourth normal quality control sample and a third abnormal quality control sample, the AA inhibition rate of the fourth normal quality control sample is greater than 50% or the ADP inhibition rate is greater than 30%, and the AA of the third abnormal quality control sample is greater than 10%. The inhibition rate is less than or equal to 50% or the ADP inhibition rate is less than or equal to 30%; the first hypercoagulable quality control sample, the first normal quality control sample, the first hypocoagulable quality control sample, the second hypercoagulable quality control sample, the second normal quality control sample, the second hypocoagulable quality control sample, the third normal quality control sample, the first abnormal quality control sample, the first high value quality control sample, the fourth normal quality control sample, the second abnormal quality control sample, the fourth normal quality control sample and the third abnormal quality control sample include deproteinized serum matrix, coagulation factors and fibrinogen.
[0005] In the present application, the inter-laboratory quality assessment samples of the thromboelastometry test reagents include one or more quality control sample groups, each group containing multiple levels of quality control samples, which can evaluate the quality of the thromboelastometry test reagents from multiple dimensions and multiple levels, thereby ensuring the stability and reliability of the thromboelastometry test reagents, and further ensuring the accuracy of the thromboelastometry test results.
[0006] Optionally, at least one of the first hypercoagulable quality control sample, the first normal quality control sample, the first hypocoagulable quality control sample, the second hypercoagulable quality control sample, the second normal quality control sample, the second hypocoagulable quality control sample, the fourth normal quality control sample and the third abnormal quality control sample also includes lyophilized platelet powder.
[0007] Optionally, the platelet freeze-dried powder includes platelets and a freeze-drying buffer reagent. Further, the freeze-drying buffer reagent includes sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate, citric acid, sodium citrate, sodium acetate, glucose, trehalose and alprostadil.
[0008] Optionally, the second high coagulable quality control sample, the second normal quality control sample and the second low coagulable quality control sample also include phospholipids.
[0009] Optionally, the third normal quality control sample also includes at least one of heparinase and protamine.
[0010] Optionally, the first abnormal quality control sample also includes a thrombin inhibitor.
[0011] Optionally, the fourth normal quality control sample also includes a platelet inhibitor.
[0012] Optionally, the third abnormal quality control sample also includes a platelet inhibitor.
[0013] In the second aspect, the present application provides a method for preparing an inter-laboratory quality assessment sample for a thromboelastogram experimental reagent, comprising mixing deproteinized serum matrix, coagulation factors and fibrinogen to prepare an inter-laboratory quality assessment sample, wherein the inter-laboratory quality assessment sample comprises at least one of a kaolin group, a rapid kaolin group, a heparinase group, a fibrinogen group and a platelet inhibitor group; the kaolin group comprises a first high coagulation quality control sample, a first normal quality control sample and a first low coagulation quality control sample, the R value of the first high coagulation quality control sample is less than 4min and the MA value is greater than 65mm, the R value of the first normal quality control sample is 4min-7min and the MA value is 45mm -65mm, the R value of the first low coagulation quality control sample is greater than 7min and the MA value is less than 45mm; the rapid kaolin group includes the second high coagulation quality control sample, the second normal quality control sample and the second low coagulation quality control sample, the ACT value of the second high coagulation quality control sample is less than 86s and the MA value is greater than 65mm, the ACT value of the second normal quality control sample is 86s-118s and the MA value is 45mm-65mm, the ACT value of the second low coagulation quality control sample is greater than 118s and the MA value is less than 45mm; the heparinase group includes the third normal quality control sample and the first abnormal quality control sample, the R value of the third normal quality control sample is 普通杯 With R 肝素酶杯 The difference between the values of the first abnormal quality control sample is less than or equal to 2min. 普通杯 With R 肝素酶杯 The difference is greater than 2min; the fibrinogen group includes a first high-value quality control sample, a fourth normal quality control sample and a second abnormal quality control sample, the MA value of the first high-value quality control sample is greater than 24mm, the MA value of the fourth normal quality control sample is 11mm-24mm, and the MA value of the second abnormal quality control sample is less than 11mm; the platelet inhibitor group includes a fourth normal quality control sample and a third abnormal quality control sample, the AA inhibition rate of the fourth normal quality control sample is greater than 50% or the ADP inhibition rate is greater than 30%, and the AA inhibition rate of the third abnormal quality control sample is less than or equal to 50% or the ADP inhibition rate is less than or equal to 30%.
[0014] Optionally, the preparation method further comprises mixing the platelet freeze-dried powder with the deproteinized serum matrix, the coagulation factor and the fibrinogen to prepare the inter-laboratory quality assessment sample.
[0015] Optionally, the preparation of the platelet freeze-dried powder includes: centrifuging platelet-rich plasma to obtain a first supernatant and a first precipitate, resuspending the first precipitate with a freeze-drying buffer to obtain a pre-treated sample, wherein the freeze-drying buffer includes 10mM-100mM sodium chloride, 0.5mM-5mM potassium chloride, 0.1mM-5mM calcium chloride, 0.2mM-5mM magnesium sulfate, 5mM-300mM sodium bicarbonate, 0.1mM-35mM citric acid, 1mM-100mM sodium citrate, 0.5mM-150mM sodium acetate, 1mM-100mM glucose, 5mM-300mM trehalose and 0.1μg / ml-10μg / ml alprostadil; centrifuging the pre-treated sample to obtain a second supernatant and a second precipitate, resuspending the second precipitate with the freeze-drying buffer to obtain a freeze-dried liquid; and freeze-drying the freeze-dried liquid to obtain the platelet freeze-dried powder.
[0016] Furthermore, the freeze-drying includes pre-freezing at -45°C to -35°C for 120min to 200min, then heating to -25°C to -15°C and maintaining for more than 1000min, and finally heating to 20°C to 35°C and maintaining for more than 360min.
[0017] Optionally, the preparation method of the deproteinized serum matrix, the coagulation factor and the fibrinogen includes: centrifuging the blood after anticoagulation treatment and collecting plasma; freezing and rethawing the plasma and then centrifuging to obtain a first supernatant and a first precipitate, dissolving the first precipitate and then centrifuging to obtain the upper liquid which is the fibrinogen; subjecting the first supernatant to protein precipitation and obtaining a second supernatant and a second precipitate by centrifugation, the second supernatant being the deproteinized serum matrix; dissolving the second precipitate and placing it in a dialysis bag for dialysis, and then centrifuging and concentrating the liquid in the dialysis bag to obtain the coagulation factor.
[0018] The second aspect of the present application provides a method for preparing an inter-laboratory quality assessment sample of a thromboelastogram test reagent that is simple in preparation and easy to operate, and can be used for large-scale production and application.
[0019] In a third aspect, the present application provides the use of the inter-laboratory quality assessment sample described in the first aspect or the inter-laboratory quality assessment sample prepared by the preparation method described in the second aspect in the quality control of thromboelastography experimental reagents.
[0020] The third aspect of the present application provides the application of the above-mentioned inter-laboratory quality assessment samples in the quality control of thromboelastometry test reagents, so as to ensure the accuracy and reliability of the thromboelastometry test reagents, and further ensure the accuracy of the thromboelastometry test results. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the following briefly introduces the drawings required for use in the embodiments or the prior art description. The specific embodiments described here are only used to explain the present application and are not used to limit the present application.
[0022] Figure 1 This is the theoretical curve of thromboelastography.
[0023] Figure 2 A flow chart of a method for preparing an inter-laboratory quality assessment sample for a thromboelastogram test reagent provided in one embodiment of the present application.
[0024] Figure 3 A flow chart of a method for preparing an inter-laboratory quality assessment sample for a thromboelastogram test reagent provided in another embodiment of the present application. DETAILED DESCRIPTION
[0025] The following is a preferred embodiment of the present application. It should be noted that a person skilled in the art may make several improvements and modifications without departing from the principles of the present application, and these improvements and modifications are also considered to be within the scope of protection of the present application.
[0026] The thromboelastogram can be obtained by the thromboelastograph, and thus the condition of the patient's blood sample, such as the time of clot formation, clot strength and fibrinolysis rate, can be obtained. The reaction cup is placed in a constant temperature cup holder, and the inner cup is inserted into the rotating shaft that is in close contact with the sensing wire; then the whole blood is mixed with the reagent and added to the outer cup. After pushing up, the blood sample contacts the inner cup, and the inner cup is immersed in the blood as a sensor; the outer cup is fixed, and the inner cup rotates at a certain angle (or the outer cup rotates and the inner cup is fixed); when the blood is not coagulated, the inner cup can rotate freely without any resistance; when the blood begins to coagulate, the viscoelasticity changes, and the rotation angle of the inner cup gradually decreases due to the resistance, which is converted into an electrical signal by a highly sensitive angle sensor, and the output curve of the coagulation strength changing with time is the thromboelastogram. Please refer to Figure 1 , is the theoretical curve of thromboelastogram, which reflects the different stages of blood coagulation. The horizontal axis is time (t / min) and the vertical axis is the strength amplitude of blood coagulation (mm); R value is the time of initial fibrin formation; K value is the time required from the end of R time to the amplitude of the tracing reaching 20mm, reflecting the rate of blood clot formation; α is the angle between the tangent of the maximum curve arc and the horizontal line, reflecting the rate of blood clot aggregation; MA value is the maximum amplitude, reflecting the maximum strength of the blood clot; ACT value is the activation time of whole blood coagulation; R 普通杯 is the R value without heparin, R 肝素酶杯 The R value when heparinase was added; the maximum amplitude (MA) of the thromboelastogram of platelets was measured in citrate anticoagulated whole blood samples, and the strength of the fibrinogen-induced clot (MA) was measured in heparin anticoagulated whole blood samples.F ), heparin anticoagulated whole blood samples were also used to measure adenosine diphosphate (ADP)-induced clot strength (MA ADP ), heparin-anticoagulated whole blood samples were also used to measure arachidonic acid (AA)-induced clot strength (MA AA ), AA inhibition rate is the inhibition rate of arachidonic acid on platelets, ADP inhibition rate is the inhibition rate of adenosine diphosphate on platelets, AA inhibition rate = (MA-MA AA ) / (MA-MA F ), ADP inhibition rate = (MA-MA ADP ) / (MA-MA F ).
[0027] The present application provides an inter-laboratory quality assessment sample of a thromboelastogram test reagent, wherein the inter-laboratory quality assessment sample comprises at least one of a kaolin group, a rapid kaolin group, a heparinase group, a fibrinogen group, and a platelet inhibitor group; the kaolin group comprises a first high coagulation quality control sample, a first normal quality control sample, and a first low coagulation quality control sample, wherein the R value of the first high coagulation quality control sample is less than 4min and the MA value is greater than 65mm, the R value of the first normal quality control sample is 4min-7min and the MA value is 45mm-65mm, and the R value of the first low coagulation quality control sample is greater than 10mm. The rapid kaolin group included the second high coagulation quality control sample, the second normal quality control sample, and the second low coagulation quality control sample. The ACT value of the second high coagulation quality control sample was less than 86s and the MA value was greater than 65mm. The ACT value of the second normal quality control sample was 86s-118s and the MA value was 45mm-65mm. The ACT value of the second low coagulation quality control sample was greater than 118s and the MA value was less than 45mm. The heparinase group included the third normal quality control sample and the first abnormal quality control sample. The R 普通杯 With R 肝素酶杯 The difference is less than or equal to 2min, and the R 普通杯 With R 肝素酶杯The difference is greater than 2min; the fibrinogen group includes the first high value quality control sample, the fourth normal quality control sample and the second abnormal quality control sample, the MA value of the first high value quality control sample is greater than 24mm, the MA value of the fourth normal quality control sample is 11mm-24mm, and the MA value of the second abnormal quality control sample is less than 11mm; the platelet inhibitor group includes the fourth normal quality control sample and the third abnormal quality control sample, the AA inhibition rate of the fourth normal quality control sample is greater than 50% or the ADP inhibition rate is greater than 30%, and the AA inhibition rate of the third abnormal quality control sample is less than or equal to 50% or the ADP inhibition rate is less than or equal to 30%; the first high coagulation quality control sample, the first normal quality control sample, the first low coagulation quality control sample, the second high coagulation quality control sample, the second normal quality control sample, the second low coagulation quality control sample, the third normal quality control sample, the first abnormal quality control sample, the first high value quality control sample, the fourth normal quality control sample, the second abnormal quality control sample, the fourth normal quality control sample and the third abnormal quality control sample include deproteinized serum matrix, coagulation factors and fibrinogen.
[0028] There are no inter-laboratory quality assessment samples for thromboelastometry test reagents in the related art, so it is impossible to determine whether the thromboelastometry test reagents are reliable and whether they have an impact on the test results. In view of this, the present application provides inter-laboratory quality assessment samples for the above-mentioned thromboelastometry test reagents, which include one or more groups of quality control sample groups, each group containing multiple levels of quality control samples, which can evaluate the quality of the thromboelastometry test reagents from multiple dimensions and multiple levels, thereby ensuring the stability and reliability of the thromboelastometry test reagents, and then ensuring the accuracy of the thromboelastometry test results; users can perform corresponding tests on the inter-laboratory quality assessment samples of the above-mentioned thromboelastometry test reagents, and evaluate the reliability of the thromboelastometry test reagents based on the difference between the test results and the performance corresponding to the inter-laboratory quality assessment samples of the thromboelastometry test reagents. Specifically, the kaolin group is used to detect whether the quality of the kaolin activator is qualified, the rapid kaolin group is used to detect whether the quality of the rapid kaolin activator is qualified, the heparinase group is used to detect whether the quality of the heparinase is qualified, the fibrinogen group is used to detect whether the quality of the fibrinogen is qualified, and the platelet inhibitor group is used to detect whether the quality of adenosine diphosphate and arachidonic acid is qualified.
[0029] In the present application, the deproteinized serum matrix, coagulation factors and fibrinogen are separated and obtained from animal blood. The animal blood may be, but is not limited to, human blood, sheep blood, pig blood, rabbit blood, cow blood, horse blood, etc., wherein human blood may be, but is not limited to, citrate anticoagulated whole blood, heparin anticoagulated whole blood, EDTA anticoagulated plasma, etc.
[0030] In an embodiment of the present application, the second high coagulation quality control sample, the second normal quality control sample, and the second low coagulation quality control sample further include phospholipids, thereby providing a reaction surface for the tissue factor to perform an activation function. Specifically, the phospholipids may be, but are not limited to, animal lecithin, plant phospholipids, etc., and the content of phospholipids in the second high coagulation quality control sample, the second normal quality control sample, or the second low coagulation quality control sample may be, but are not limited to, 0.00000001 μg to 100 μg, 0.01 μg to 80 μg, 0.1 μg to 65 μg, or 100 μg to 25 μg, etc.
[0031] In the embodiment of the present application, the third normal quality control sample further includes at least one of heparinase and protamine. By adding heparinase and / or protamine to decompose heparin, the R of the third normal quality control sample formed by the deproteinized serum matrix, coagulation factors and fibrinogen is further ensured. 普通杯 With R 肝素酶杯 Specifically, the content of heparinase and / or protamine in the third normal quality control sample may be, but is not limited to, 0.00000001 μg to 100 mg, 0.01 μg to 80 mg, 0.1 μg to 50 mg, or 100 μg to 20 mg.
[0032] In the embodiment of the present application, the first abnormal quality control sample further includes a thrombin inhibitor. By adding the thrombin inhibitor, the R of the first abnormal quality control sample formed by the deproteinized serum matrix, coagulation factors and fibrinogen is further ensured. 普通杯 With R 肝素酶杯 The difference is greater than 2min. Specifically, the thrombin inhibitor may include, but is not limited to, unfractionated heparin, low molecular weight heparin, enoxaparin sodium, dalteparin sodium, hirudin, recombinant hirudin, antithrombin III, aprotinin, phenylalanyl-prolyl-arginine chloromethyl ketone and (2R, 4R)-4-methyl-1-[N-[(3-methyl-1,2,3,4-tetrahydro-8-quinolyl)sulfonyl]-L-arginyl]-2-piperidinic acid. One or more. Specifically, the content of the thrombin inhibitor in the first abnormal quality control sample may be, but is not limited to, 0.00000001 μg to 100 mg, 0.01 μg to 80 mg, 0.1 μg to 50 mg, or 100 μg to 20 mg, etc.
[0033] In an embodiment of the present application, the fourth normal quality control sample also includes a platelet inhibitor. In an embodiment of the present application, the third abnormal quality control sample also includes a platelet inhibitor. By adding a platelet inhibitor, the inhibition rate of the fourth normal quality control sample and the third abnormal quality control sample is within the required range. Specifically, platelet inhibitors may include, but are not limited to, aspirin, Plavix, Ticlid, Prasugrel, Ticagrelor, Cangrelor, Tirofiban, Eptifibatide, Abciximab, platelet glycoprotein IIb / IIIa receptor polyclonal antibody, etc. Specifically, the content of platelet inhibitors in the fourth normal quality control sample or the third abnormal quality control sample may be, but is not limited to, 0.00000001 μg to 100 mg, 0.1 μg to 90 mg, 1 μg to 75 mg, or 100 μg to 30 mg, etc.
[0034] In the embodiment of the present application, at least one of the first hypercoagulable quality control sample, the first normal quality control sample, the first low coagulation quality control sample, the second hypercoagulable quality control sample, the second normal quality control sample, the second low coagulation quality control sample, the fourth normal quality control sample and the third abnormal quality control sample also includes platelet freeze-dried powder. The addition of platelet freeze-dried powder makes it easier to make the deproteinized serum matrix, coagulation factors and fibrinogen cooperate to obtain the quality control sample of the required index. In the embodiment of the present application, platelet freeze-dried powder includes platelets and freeze-dried buffer reagent. By adding freeze-dried buffer reagent, platelets are protected, the environmental sensitivity of platelets is reduced, and the biological properties of platelets are guaranteed. Further, freeze-dried buffer reagent includes sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate, citric acid, sodium citrate, sodium acetate, glucose, trehalose and alprostadil. The substance of the freeze-dried buffer can protect platelets, and can also enter platelet cells to further protect platelets. Furthermore, the freeze-dried buffer reagent also includes at least one of plasma and bovine serum albumin, which can enter the platelet cells, protect the platelets, further reduce the environmental sensitivity of the platelets, and ensure the biological properties of the platelets.
[0035] The present application provides a method for preparing an inter-laboratory quality assessment sample for a thromboelastogram test reagent, comprising mixing a deproteinized serum matrix, coagulation factors and fibrinogen to prepare an inter-laboratory quality assessment sample in any of the above-mentioned embodiments, wherein the inter-laboratory quality assessment sample comprises at least one of a kaolin group, a rapid kaolin group, a heparinase group, a fibrinogen group and a platelet inhibitor group.
[0036] In an embodiment of the present application, the preparation method of deproteinized serum matrix, coagulation factors and fibrinogen includes: centrifuging the blood after anticoagulation treatment and collecting plasma; freezing and rethawing the plasma and then centrifuging to obtain a first supernatant and a first precipitate, dissolving the first precipitate and then centrifuging to obtain the upper liquid as fibrinogen; subjecting the first supernatant to protein precipitation and obtaining a second supernatant and a second precipitate by centrifugation, the second supernatant being the deproteinized serum matrix; dissolving the second precipitate and placing it in a dialysis bag for dialysis, and then centrifuging and concentrating the liquid in the dialysis bag to obtain the coagulation factor.
[0037] See also Figure 2 , is a flow chart of a method for preparing an external quality assessment sample of a thromboelastogram test reagent provided in one embodiment of the present application, comprising:
[0038] S101: After the blood is anticoagulated, it is centrifuged and the plasma is collected.
[0039] S102: The plasma is frozen, thawed and then centrifuged to obtain a first supernatant and a first precipitate. The first precipitate is dissolved and then centrifuged to obtain an upper layer of fibrinogen.
[0040] S103: performing protein precipitation on the first supernatant, and obtaining a second supernatant and a second precipitate by centrifugation, wherein the second supernatant is a deproteinized serum matrix.
[0041] S104: dissolving the second precipitate and placing it in a dialysis bag for dialysis, and then centrifuging and concentrating the liquid in the dialysis bag to obtain the coagulation factor.
[0042] S105: Mix the deproteinized serum matrix, coagulation factors and fibrinogen to prepare the external quality control sample.
[0043] In S101, the blood may be, but is not limited to, human blood, sheep blood, pig blood, rabbit blood, cow blood, horse blood, etc. In one embodiment, the blood anticoagulation treatment includes mixing the blood with a citrate anticoagulant. Specifically, the mixing ratio of the blood to the citrate anticoagulant is 9:1 by weight.
[0044] In S102, a blood clot, i.e., a first precipitate, is produced by freezing and thawing the plasma. In one embodiment, the freezing temperature is -30°C to -15°C, and the freezing time is greater than or equal to 12 hours. Further, the freezing temperature is -25°C to -20°C, and the freezing time is 12h-18h. In one embodiment, the thawing temperature is 2°C to 8°C, and the thawing time is greater than or equal to 12h. Further, the thawing temperature is 3°C to 6°C, and the thawing time is 12h-18h. The biological properties of fibrinogen are further guaranteed by the above-mentioned freezing and thawing processes.
[0045] In S103, the protein precipitation may be, but is not limited to, ammonium sulfate precipitation, and the deproteinized serum matrix may be stored at 2°C to 8°C for a short term, or below -20°C for a long term.
[0046] In S104, the second precipitate may be dissolved with, but is not limited to, physiological saline, and the molecular weight cutoff of the dialysis bag may be, but is not limited to, 3 kDa.
[0047] In S105, the deproteinized serum matrix, coagulation factors and fibrinogen are mixed to prepare an external quality assessment sample. In one embodiment, the deproteinized serum matrix, coagulation factors and fibrinogen can be freeze-dried to obtain deproteinized serum matrix dry powder, coagulation factor dry powder and fibrinogen dry powder, and the deproteinized serum matrix dry powder, coagulation factor dry powder and fibrinogen dry powder are mixed to prepare an external quality assessment sample.
[0048] In an embodiment of the present application, the preparation method further comprises mixing the platelet freeze-dried powder with deproteinized serum matrix, coagulation factors and fibrinogen to prepare an inter-laboratory quality assessment sample.
[0049] In an embodiment of the present application, the preparation of platelet lyophilized powder includes: centrifuging platelet-rich plasma to obtain a first supernatant and a first precipitate, resuspending the first precipitate with a lyophilization buffer to obtain a pre-treated sample, wherein the lyophilization buffer includes 10mM-100mM sodium chloride, 0.5mM-5mM potassium chloride, 0.1mM-5mM calcium chloride, 0.2mM-5mM magnesium sulfate, 5mM-300mM sodium bicarbonate, 0.1mM-35mM citric acid, 1mM-100mM sodium citrate, 0.5mM-150mM sodium acetate, 1mM-100mM glucose, 5mM-300mM trehalose and 0.1μg / ml-10μg / ml alprostadil; centrifuging the pre-treated sample to obtain a second supernatant and a second precipitate, resuspending the second precipitate with a lyophilization buffer to obtain a lyophilized liquid; and lyophilizing the lyophilized liquid to obtain platelet lyophilized powder.
[0050] See also Figure 3 , is a flow chart of a method for preparing an inter-laboratory quality assessment sample of a thromboelastogram test reagent provided in another embodiment of the present application, comprising:
[0051] S201: After centrifuging the platelet-rich plasma, a first supernatant and a first precipitate are obtained, and the first precipitate is resuspended with a freeze-drying buffer to obtain a pre-treated sample.
[0052] S202: centrifuging the pre-treated sample to obtain a second supernatant and a second precipitate, resuspending the second precipitate with a lyophilization buffer to obtain a lyophilized liquid; and lyophilizing the lyophilized liquid to obtain lyophilized platelet powder.
[0053] S203: Mix the deproteinized serum matrix, coagulation factors, fibrinogen and platelet lyophilized powder to prepare the external quality assessment sample.
[0054] In S201, the platelet-rich plasma may be, but is not limited to, human blood, sheep blood, pig blood, rabbit blood, cow blood, horse blood, etc. In an embodiment of the present application, the method for preparing platelet-rich plasma includes: centrifuging the blood and then centrifuging the supernatant for a second time to obtain a platelet-rich plasma precipitate.
[0055] In S202, the first precipitate can be resuspended with the same volume of freeze-dried buffer as the second supernatant. In one embodiment, the pre-treated sample is subjected to oscillation treatment to ensure that the platelets remain suspended. Specifically, it can be, but is not limited to, oscillating in a 37° C. water bath for 4 hours. In the present application, the speed and time of centrifugation are selected as needed and are not limited thereto.
[0056] In the present application embodiment, the freeze-dried buffer includes 10mM-100mM sodium chloride, 0.5mM-5mM potassium chloride, 0.1mM-5mM calcium chloride, 0.2mM-5mM magnesium sulfate, 5mM-300mM sodium bicarbonate, 0.1mM-35mM citric acid, 1mM-100mM sodium citrate, 0.5mM-150mM sodium acetate, 1mM-100mM glucose, 5mM-300mM trehalose and 0.1μg / ml-10μg / ml alprostadil. The inventors have found that when the above-mentioned freeze-dried buffer is used to resuspend platelets, platelets can be protected, platelets with good performance are obtained, and the preparation of inter-laboratory quality assessment samples is conducive to. In one embodiment of the present application, the lyophilization buffer includes 20mM-80mM sodium chloride, 1mM-3mM potassium chloride, 0.5mM-3mM calcium chloride, 1mM-3mM magnesium sulfate, 15mM-200mM sodium bicarbonate, 1mM-20mM citric acid, 5mM-70mM sodium citrate, 10mM-100mM sodium acetate, 5mM-60mM glucose, 30mM-200mM trehalose and 1μg / ml-5μg / ml alprostadil. Further, lyophilized buffer comprises 40mM-60mM sodium chloride, 1mM-3mM potassium chloride, 0.5mM-1mM calcium chloride, 1mM-3mM magnesium sulfate, 20mM-50mM sodium bicarbonate, 1mM-5mM citric acid, 5mM-10mM sodium citrate, 10mM-20mM sodium acetate, 5mM-15mM glucose, 30mM-60mM trehalose and 1μg / ml-5μg / ml alprostadil.Specifically, alprostadil can be dissolved in physiological saline and added in lyophilized buffer.In the present application, lyophilized buffer can be filtered and sterilized by 0.22μm filter.
[0057] In an embodiment of the present application, after the second precipitate is resuspended in the freeze-drying buffer, at least one of plasma and bovine serum albumin can be added to obtain a freeze-dried liquid. Adding plasma or bovine serum albumin can further protect platelets. In an embodiment of the present application, the mass content of plasma in the freeze-dried liquid is 30%-40%. Further, the mass content of plasma in the freeze-dried liquid is 32%-37%. In another embodiment of the present application, the mass content of bovine serum albumin in the freeze-dried liquid is 0.1%-10%. Further, the mass content of bovine serum albumin in the freeze-dried liquid is 1%-8%.
[0058] In an embodiment of the present application, freeze drying includes pre-freezing at -45°C to -35°C for 120min-200min, then heating to -25°C to -15°C and maintaining for more than 1000min, and finally heating to 20°C-35°C and maintaining for more than 360min. In this way, the biological activity of platelets is guaranteed. In one embodiment, freeze drying is carried out in a freeze dryer, and the condenser temperature of the freeze dryer is -75°C to -70°C to ensure the freeze drying. In another embodiment, the vacuum degree of pre-freezing is less than 133mBar; when heated to -25°C to -15°C, the vacuum degree is less than 0.5mBar. In another embodiment, freeze drying includes pre-freezing at -45°C to -35°C for 120min-200min, then heating to -25°C to -15°C within 20min-40min and maintaining for more than 1000min, and finally heating to 20°C-35°C within 30min-50min and maintaining for more than 360min. In another embodiment, the lyophilized liquid may be placed in an ultra-low temperature refrigerator for pretreatment before being lyophilized. The temperature of the ultra-low temperature refrigerator may be, but is not limited to, -80°C.
[0059] In S203, the deproteinized serum matrix, coagulation factors, fibrinogen and platelet lyophilized powder are mixed to prepare an external quality assessment sample.
[0060] In the present application, the deproteinized serum matrix, coagulation factors and fibrinogen can be mixed in proportion, such as a volume ratio of 1:1:1, 1:2:1 or 1:3:1, and the contents of the deproteinized serum matrix, coagulation factors and fibrinogen can be adjusted according to the test results.
[0061] In one embodiment of the present application, the deproteinized serum matrix, coagulation factors and fibrinogen are mixed in a volume ratio of 1:3:1, and then freeze-dried platelet powder is added. The sample is tested using a thromboelastograph and a kaolin reagent to obtain R value and MA value. If the R value is less than 4min and the MA value is greater than 65mm, the sample is the first high coagulation quality control sample; the deproteinized serum matrix, coagulation factors and fibrinogen are mixed in a volume ratio of 1:2:1, and then freeze-dried platelet powder is added. The sample is tested using a thromboelastograph and a kaolin reagent to obtain R value and MA value. If the R value is 4min-7m in and the MA value is 45mm-65mm, then the sample is the first normal quality control sample; the deproteinized serum matrix, coagulation factors and fibrinogen are mixed in a volume ratio of 1:1:1 and then added to the platelet freeze-dried powder, and the sample is tested using a thrombelastograph and kaolin reagent to obtain the R value and MA value. If the R value is greater than 7min and the MA value is less than 45mm, then the sample is the first low coagulation quality control sample; if the R value and MA value are out of the range, judge according to the specific R value and MA value, and continue to add at least one of the deproteinized serum matrix, coagulation factors, fibrinogen and platelet freeze-dried powder.
[0062] In one embodiment of the present application, the deproteinized serum matrix, coagulation factors and fibrinogen are mixed in a volume ratio of 1:3:1, and then freeze-dried platelet powder and phospholipids are added. The sample is tested using a thromboelastograph and a kaolin reagent to obtain ACT and MA values. If the ACT value is less than 86s and the MA value is greater than 65mm, the sample is a second high coagulation quality control sample; the deproteinized serum matrix, coagulation factors and fibrinogen are mixed in a volume ratio of 1:2:1, and then freeze-dried platelet powder and phospholipids are added. The sample is tested using a thromboelastograph and a kaolin reagent to obtain ACT and MA values. If the ACT value is 86s-11 8s and the MA value is 45mm-65mm, then the sample is the second normal quality control sample; the deproteinized serum matrix, coagulation factors and fibrinogen are mixed in a volume ratio of 1:1:1, and then platelet freeze-dried powder and phospholipids are added. The sample is tested using a thromboelastogram and kaolin reagent to obtain the ACT value and MA value. If the ACT value is greater than 118s and the MA value is less than 45mm, then the sample is the second low coagulation quality control sample; if the ACT value and MA value are out of the range, at least one of the deproteinized serum matrix, coagulation factors, fibrinogen and platelet freeze-dried powder shall be added according to the specific ACT value and MA value.
[0063] In one embodiment of the present application, the deproteinized serum matrix, coagulation factors and fibrinogen were mixed in a volume ratio of 1:1:1, and the sample was tested with a thromboelastometry instrument and a kaolin reagent to obtain R 普通杯 The sample was tested with heparinase cup reagent to obtain R 肝素酶杯 If R 普通杯 With R 肝素酶杯If the difference between R and 普通杯 With R 肝素酶杯 The difference is not within the range, depending on the specific R 普通杯 With R 肝素酶杯 The difference between the two values is judged by adding heparinase, protamine, etc.; if R 普通杯 With R 肝素酶杯 If the difference between R and 普通杯 With R 肝素酶杯 The difference is not within the range, depending on the specific R 普通杯 With R 肝素酶杯 Based on the difference in the value of , add thrombin inhibitor.
[0064] In one embodiment of the present application, after deproteinized serum matrix, coagulation factors and fibrinogen are mixed in a volume ratio of 1:1:1, the sample is tested using a thrombelastograph and a functional fibrinogen detection reagent to obtain the MA value. If the MA value is greater than 24 mm, the sample is the first high-value quality control sample. If the MA value is too small, fibrinogen can be added to adjust the MA value to be greater than 24 mm; if the MA value is 11 mm-24 mm, the sample is the fourth normal quality control sample; if the MA value is less than 11 mm, the sample is the second abnormal quality control sample. If the MA value is too large, deproteinized serum matrix can be added to adjust the MA value to be less than 11 mm.
[0065] In one embodiment of the present application, the deproteinized serum matrix, coagulation factors and fibrinogen were mixed in a volume ratio of 1:1:1 and then added to the platelet freeze-dried powder. The sample was tested using a thromboelastograph and platelet detection reagents (kaolin, activator F, activator ADP / activator AA) to obtain the MA values (MA, MA) of the samples tested by each detection reagent. F 、MA ADP / MA AA ), calculate the inhibition rate of ADP or AA on platelets. If the AA inhibition rate is greater than 50% or the ADP inhibition rate is greater than 30%, the sample is the fourth normal quality control sample. If the AA inhibition rate is less than or equal to 50% or the ADP inhibition rate is less than or equal to 30%, the sample is the third abnormal quality control sample. If the inhibition rate does not meet the standard, a platelet inhibitor can be added.
[0066] It can be understood that the above embodiment is only an exemplary illustration of the preparation process of the inter-laboratory quality assessment sample. Several modifications and improvements can be made on this basis, all of which belong to the protection scope of the present application, and the inter-laboratory quality assessment sample of the thromboelastography test reagent of the present application can be obtained.
[0067] The preparation method of the inter-laboratory quality assessment sample of the thromboelastogram test reagent provided in the present application is simple and easy to operate, and can be used for large-scale production and application.
[0068] The present application also provides the use of the above-mentioned external quality assessment samples of thromboelastometry test reagents in the quality control of thromboelastometry test reagents, thereby ensuring the accuracy and reliability of the thromboelastometry test reagents, and further ensuring the accuracy of the thromboelastometry test results.
[0069] In the embodiment of the present application, the inter-laboratory quality assessment sample of the above-mentioned thromboelastogram test reagent is mixed with the corresponding test reagent, and the corresponding test results, such as R value, MA value, ACT value, R 普通杯 Value, R 肝素酶杯 value, AA inhibition rate, ADP inhibition rate, etc., and these test results were compared with the R value, MA value, ACT value, R 普通杯 Value, R 肝素酶杯 The standard value of the AA inhibition rate or the ADP inhibition rate is compared to determine the quality of the corresponding experimental reagent. In one embodiment of the present application, the quality of the corresponding experimental reagent is determined by obtaining the deviation between the test result and the standard value. The calculation formula of the deviation is shown in formula (1):
[0070]
[0071] In an embodiment of the present application, when the deviation is within an acceptable range, the quality of the thromboelastometry test reagent is considered to be qualified. In one embodiment, when the inter-laboratory quality assessment samples of the thromboelastometry test reagent include a kaolin group, when the R value deviation is less than or equal to 15%, and the MA value deviation is less than or equal to 10%, the quality of the kaolin activator is qualified. In one embodiment, when the inter-laboratory quality assessment samples of the thromboelastometry test reagent include a rapid kaolin group, when the ACT value deviation is less than or equal to 15%, and the MA value deviation is less than or equal to 10%, the quality of the rapid kaolin activator is qualified. In one embodiment, when the inter-laboratory quality assessment samples of the thromboelastometry test reagent include a heparinase group, when the R 普通杯 With R 肝素酶杯 When the deviation of the difference is less than or equal to 15%, the heparinase quality is qualified. In one embodiment, when the inter-laboratory quality assessment sample of the thromboelastogram test reagent includes a fibrinogen group, when the MA value deviation is less than or equal to 15%, the fibrinogen quality is qualified. In one embodiment, when the inter-laboratory quality assessment sample of the thromboelastogram test reagent includes a platelet inhibitor group, when the MA value (MA AA or MA ADP) When the deviation is less than or equal to 10%, the quality of arachidonic acid or adenosine diphosphate is qualified. Further, at least one of the kaolin group, rapid kaolin group, heparinase group, fibrinogen group and platelet inhibitor group is subjected to multiple experiments, and the total number of experiments and the number of qualified quality are counted to obtain the score of the thromboelastogram test reagent, wherein the score is the ratio of the number of qualified quality to the total number of experiments. Further, when the score is greater than or equal to 90%, the quality of the thromboelastogram test reagent is evaluated to be qualified, otherwise the quality is unqualified. In a specific embodiment, a total of five quality control sample groups, including the kaolin group, rapid kaolin group, heparinase group, fibrinogen group and platelet inhibitor group, are used to test the quality of the thromboelastogram test reagent. It can be seen that the quality of the thromboelastogram test reagent is qualified only when the deviation of the test results corresponding to at least four quality control sample groups and the standard value is within an acceptable range. Therefore, the inter-laboratory quality assessment samples of the thromboelastometry test reagents provided in this application can be used to judge the quality of the thromboelastometry test reagents, thereby avoiding the influence of the thromboelastometry test reagents on the test results; when the quality of the thromboelastometry test reagents is unqualified, the thromboelastometry test reagents are targeted for testing and replacement to ensure the subsequent testing.
[0072] In one embodiment, the method for using the kaolin group in the inter-laboratory quality assessment sample of the thromboelastogram experimental reagent can be: dissolve the first hypercoagulable quality control sample, the first normal quality control sample or the first hypocoagulable quality control sample in water, and add the kaolin activator to be tested, add the mixture into a reaction cup, add calcium chloride into the reaction cup, place it in a thromboelastogram instrument for coagulation test, and obtain the detected R value and MA value according to the thromboelastogram; compare the detected R value and MA value with the standard R value and MA value corresponding to the first hypercoagulable quality control sample, the first normal quality control sample, and the first hypocoagulable quality control sample, so as to determine whether the kaolin activator to be tested is qualified.
[0073] In one embodiment, the method for using the rapid kaolin group in the inter-laboratory quality assessment sample of the thromboelastogram experimental reagent can be: add the rapid kaolin activator to be tested and calcium chloride into a reaction cup, dissolve the second high coagulation quality control sample, the second normal quality control sample or the second low coagulation quality control sample in water and add it to the reaction cup, mix well and place the reaction cup in a thromboelastogram instrument for coagulation test, and obtain the detected ACT value and MA value according to the thromboelastogram; compare the detected ACT value and MA value with the standard ACT value and MA value corresponding to the second high coagulation quality control sample, the second normal quality control sample, and the second low coagulation quality control sample, so as to determine whether the rapid kaolin activator to be tested is qualified.
[0074] In one embodiment, the method for using the heparinase group in the inter-laboratory quality assessment sample of the thromboelastometry test reagent can be: the sample obtained by mixing citrate anticoagulated whole blood and kaolin activator is added to a common cup (blank reaction cup) and a heparinase cup (reaction cup containing the heparinase to be detected), and calcium chloride is added to both the common cup and the heparinase cup, and then the cup is placed in a thromboelastometry instrument for coagulation test, and R is obtained according to the thromboelastometry. 普通杯 With R 肝素酶杯 , and calculate the detected R 普通杯 With R 肝素酶杯 The difference between the detected R 普通杯 With R 肝素酶杯 The difference between the third normal quality control sample and the first abnormal quality control sample corresponds to the standard R 普通杯 With R 肝素酶杯 The difference is compared to determine whether the heparinase to be tested is qualified.
[0075] In one embodiment, the method for using the fibrinogen group in the inter-laboratory quality assessment sample of the thromboelastogram experimental reagent can be: after dissolving the first high-value quality control sample, the fourth normal quality control sample or the second abnormal quality control sample, add the fibrin reagent to be tested, add the mixed mixture into a reaction cup containing calcium chloride, place it in a thromboelastogram instrument for coagulation test, and obtain the detected MA value according to the thromboelastogram; compare the detected MA value with the standard MA value corresponding to the first high-value quality control sample, the fourth normal quality control sample, and the second abnormal quality control sample, so as to determine whether the fibrin reagent to be tested is qualified.
[0076] In one embodiment, the method for using the platelet inhibitor group in the inter-laboratory quality assessment sample of the thromboelastogram experimental reagent can be: the activator F, the arachidonic acid to be detected, and the adenosine diphosphate to be detected are resuspended in water to obtain the activator F solution, the AA solution, and the ADP solution, the activator F solution and the AA solution are added to a reaction cup, and the activator F solution and the ADP solution are added to the reaction cup; the fourth normal quality control sample and the third abnormal quality control sample are dissolved in water, and then added to the above-mentioned reaction cups respectively, and placed in the thromboelastogram instrument for coagulation test, and the detected MA is obtained according to the thromboelastogram. AA Value, MA ADP Value; MA of detection AA Value, MA ADP The value is the same as the standard MA corresponding to the fourth normal quality control sample and the third abnormal quality control sample AA Value, MA ADP The values are compared to determine whether the arachidonic acid and adenosine diphosphate to be tested are qualified.
[0077] It can be understood that the above embodiments are only illustrative of the use of inter-laboratory quality assessment samples in evaluating the quality of thromboelastography test reagents. Different experimental processes can be carried out on this basis, such as using different blood samples, different detection methods, different mixing sequences, etc., all of which can evaluate the quality of thromboelastography test reagents and are still within the scope of protection of the present application.
[0078] Example
[0079] Fresh pig blood samples were collected, 9 pig blood samples were mixed with 1 citrate anticoagulant, and then centrifuged at 600g for 10 minutes to separate plasma from red blood cells and white blood cells; the separated plasma was frozen at -20℃ for at least 12 hours, and then thawed at 2℃-8℃ for at least 12 hours after being taken out, and blood clots were generated; the plasma was centrifuged at 600g for 10 minutes to obtain the first supernatant and the first precipitate. The first precipitate (blood clot) was slowly rinsed with water, dissolved in saline and centrifuged, and the supernatant was freeze-dried to obtain fibrinogen freeze-dried powder; the first supernatant was precipitated with ammonium sulfate, and the second supernatant and the second precipitate were obtained after centrifugation. The second supernatant was used as a deproteinized serum matrix; the second precipitate was dissolved in saline, placed in a dialysis bag with a dialysis membrane cutoff molecular weight of 3KD, added to a beaker with a 100X volume ratio for dialysis overnight, and then concentrated by centrifugation to obtain a high-concentration coagulation factor solution.
[0080] Fresh pig blood samples were collected, 9 pig blood samples and 1 citrate anticoagulant were mixed, then centrifuged at 600g for 10 minutes, all plasma was drawn and transferred to another centrifuge tube, and centrifuged at 1500g for 10 minutes. The upper supernatant was platelet-poor plasma, and the lower layer was platelet concentrate; 3 / 4 of the supernatant was drawn and discarded, and the remaining liquid was shaken to obtain platelet-rich plasma. Platelet-rich plasma was centrifuged at 1500g for 15 minutes, and the supernatant was removed. 55mM sodium chloride, 2.1mM potassium chloride, 0.7 calcium chloride, 1.1mM magnesium sulfate, 31mM sodium bicarbonate, 3.4mM citric acid, 6.7mM sodium citrate, 15mM sodium acetate, 10.7mM glucose, 50mM trehalose and 1μg / ml alprostadil were mixed to prepare a freeze-dried buffer with a pH of 6.8 and filtered with a 0.22μm filter. Resuspend the platelets with a freeze-drying buffer equal to the volume of the discarded supernatant, and place in a water bath at 37°C for 4 hours to obtain a pre-treated sample. Centrifuge the pre-treated sample, remove the supernatant, resuspend it with freeze-drying buffer, and add plasma and bovine serum albumin to obtain a lyophilized solution, in which the plasma mass content is 30% and the bovine serum albumin mass content is 2%. Transfer the lyophilized solution to a lyophilization bottle, 4 mL per bottle. Set the freeze dryer to cool for 70 minutes. After the plate layer is pre-frozen from room temperature to -45°C, move the freeze-dried bottle into the freeze dryer and put it into the -45°C plate layer for vacuum drying. The cold trap temperature is maintained at -70±5°C and the vacuum degree is <133-mbar for 180 minutes. Then gradually increase the temperature. Set the temperature increase for 30 minutes. The plate layer is increased from -45°C to -20°C. The cold trap temperature is maintained at -70±5°C and the vacuum degree is <0.5 mbar. Keep freeze-drying at -20°C for no less than 1000 minutes. Then gradually increase the temperature. Set the temperature increase for 40 minutes. The plate layer is increased from -20°C to 30°C. The cold trap temperature is maintained at -70±5°C. The plate layer is maintained at 30°C for analytical drying for no less than 360 minutes. Then, vacuum seal it with a lid, gradually let in air, and take out the platelet freeze-dried powder after the air pressure is balanced.
[0081] The deproteinized serum matrix, coagulation factors and fibrinogen were mixed, and the platelet freeze-dried powder was added to prepare the kaolin group reagent, including the first high coagulation quality control sample with an R value of less than 4min and an MA value greater than 65mm, the first normal quality control sample with an R value of 4min-7min and an MA value of 45mm-65mm, and the first low coagulation quality control sample with an R value greater than 7min and an MA value less than 45mm. The configured first high coagulation quality control sample, the first normal quality control sample and the first low coagulation quality control sample were tested on a standard thromboelastograph, and the results are shown in Table 1.
[0082] Table 1 Test results of kaolin group
[0083]
[0084] It can be seen from Table 1 that the first hypercoagulable quality control sample, the first normal quality control sample and the first hypocoagulable quality control sample obtained meet the requirements of inter-laboratory quality assessment samples and can be used as inter-laboratory quality assessment samples of thromboelastography experimental reagents. The R value of the first hypercoagulable quality control sample is 2.6 min, and the MA value is 73.2 mm; the R value of the first normal quality control sample is 5.1 min, and the MA value is 53.7 mm; the R value of the first hypocoagulable quality control sample is 9.2 min, and the MA value is 24.7 mm.
[0085] The above-mentioned kaolin group reagents were used to conduct inter-laboratory quality assessment of kaolin activators in seven hospitals. The test results of each hospital are shown in Table 2, and the deviations between the test results of each hospital and the standard R value and MA value of the first high coagulation quality control sample, the first normal quality control sample and the first low coagulation quality control sample were calculated. The results are shown in Table 3.
[0086] Table 2 External quality assessment test results
[0087]
[0088] Table 3 Deviation of external quality assessment test results
[0089]
[0090] It can be seen from Table 3 that the R value deviations of the test results of each hospital are all less than 15%, and the MA value deviations are all less than 10%, and the deviations are all within the acceptable range. The inter-laboratory quality assessment results of kaolin reagents in each hospital are qualified.
[0091] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the present application. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the present application shall be subject to the attached claims.
Claims
1. An external quality assessment sample for thromboelastography test reagents, characterized in that: The external quality assessment samples include at least one of a kaolin group, a rapid kaolin group, a heparinase group, a fibrinogen group, and a platelet inhibitor group; The kaolin group includes a first high coagulation quality control sample, a first normal quality control sample and a first low coagulation quality control sample, wherein the R value of the first high coagulation quality control sample is less than 4min and the MA value is greater than 65mm, the R value of the first normal quality control sample is 4min-7min and the MA value is 45mm-65mm, and the R value of the first low coagulation quality control sample is greater than 7min and the MA value is less than 45mm; The rapid kaolin group includes a second high coagulation quality control sample, a second normal quality control sample, and a second low coagulation quality control sample, the ACT value of the second high coagulation quality control sample is less than 86s and the MA value is greater than 65mm, the ACT value of the second normal quality control sample is 86s-118s and the MA value is 45mm-65mm, and the ACT value of the second low coagulation quality control sample is greater than 118s and the MA value is less than 45mm; The heparinase group includes a third normal quality control sample and a first abnormal quality control sample, and the R 普通杯 With R 肝素酶杯 The difference between the values of the first abnormal quality control sample is less than or equal to 2min. 普通杯 With R 肝素酶杯 The difference is greater than 2min; The fibrinogen group includes a first high-value quality control sample, a fourth normal quality control sample, and a second abnormal quality control sample, the MA value of the first high-value quality control sample is greater than 24mm, the MA value of the fourth normal quality control sample is 11mm-24mm, and the MA value of the second abnormal quality control sample is less than 11mm; The platelet inhibitor group includes a fourth normal quality control sample and a third abnormal quality control sample, wherein the AA inhibition rate of the fourth normal quality control sample is greater than 50% or the ADP inhibition rate is greater than 30%, and the AA inhibition rate of the third abnormal quality control sample is less than or equal to 50% or the ADP inhibition rate is less than or equal to 30%; The first high coagulation quality control sample, the first normal quality control sample, the first low coagulation quality control sample, the second high coagulation quality control sample, the second normal quality control sample, the second low coagulation quality control sample, the third normal quality control sample, the first abnormal quality control sample, the first high value quality control sample, the fourth normal quality control sample, the second abnormal quality control sample, the fourth normal quality control sample and the third abnormal quality control sample include deproteinized serum matrix, coagulation factors and fibrinogen.
2. The external quality assessment sample according to claim 1, characterized in that: At least one of the first hypercoagulable quality control sample, the first normal quality control sample, the first hypocoagulable quality control sample, the second hypercoagulable quality control sample, the second normal quality control sample, the second hypocoagulable quality control sample, the fourth normal quality control sample and the third abnormal quality control sample also includes lyophilized platelet powder.
3. The external quality assessment sample according to claim 2, characterized in that: The platelet freeze-dried powder comprises platelets and a freeze-drying buffer reagent; The lyophilization buffer reagent comprises sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate, citric acid, sodium citrate, sodium acetate, glucose, trehalose and alprostadil.
4. The external quality assessment sample according to claim 1, characterized in that: The second high coagulable quality control sample, the second normal quality control sample and the second low coagulable quality control sample further include phospholipids; The third normal quality control sample further includes at least one of heparinase and protamine; The first abnormal quality control sample also includes a thrombin inhibitor; The fourth normal quality control sample also includes a platelet inhibitor; The third abnormal quality control sample also includes a platelet inhibitor.
5. A method for preparing an external quality assessment sample of a thromboelastogram test reagent, characterized in that: The method comprises mixing deproteinized serum matrix, coagulation factors and fibrinogen to prepare an external quality assessment sample, wherein the external quality assessment sample comprises at least one of a kaolin group, a rapid kaolin group, a heparinase group, a fibrinogen group and a platelet inhibitor group; The kaolin group includes a first high coagulation quality control sample, a first normal quality control sample and a first low coagulation quality control sample, wherein the R value of the first high coagulation quality control sample is less than 4min and the MA value is greater than 65mm, the R value of the first normal quality control sample is 4min-7min and the MA value is 45mm-65mm, and the R value of the first low coagulation quality control sample is greater than 7min and the MA value is less than 45mm; The rapid kaolin group includes a second high coagulation quality control sample, a second normal quality control sample, and a second low coagulation quality control sample, the ACT value of the second high coagulation quality control sample is less than 86s and the MA value is greater than 65mm, the ACT value of the second normal quality control sample is 86s-118s and the MA value is 45mm-65mm, and the ACT value of the second low coagulation quality control sample is greater than 118s and the MA value is less than 45mm; The heparinase group includes a third normal quality control sample and a first abnormal quality control sample, and the R 普通杯 With R 肝素酶杯 The difference between the values of the first abnormal quality control sample is less than or equal to 2min. 普通杯 With R 肝素酶杯 The difference is greater than 2min; The fibrinogen group includes a first high-value quality control sample, a fourth normal quality control sample, and a second abnormal quality control sample, the MA value of the first high-value quality control sample is greater than 24mm, the MA value of the fourth normal quality control sample is 11mm-24mm, and the MA value of the second abnormal quality control sample is less than 11mm; The platelet inhibitor group includes a fourth normal quality control sample and a third abnormal quality control sample, the AA inhibition rate of the fourth normal quality control sample is greater than 50% or the ADP inhibition rate is greater than 30%, and the AA inhibition rate of the third abnormal quality control sample is less than or equal to 50% or the ADP inhibition rate is less than or equal to 30%.
6. The preparation method according to claim 5, characterized in that: The method also includes mixing the platelet freeze-dried powder with the deproteinized serum matrix, the coagulation factor and the fibrinogen to prepare the inter-laboratory quality assessment sample.
7. The preparation method according to claim 6, characterized in that: The preparation of the platelet freeze-dried powder comprises: The platelet-rich plasma is centrifuged to obtain a first supernatant and a first precipitate, and the first precipitate is resuspended with a lyophilization buffer to obtain a pre-treated sample, wherein the lyophilization buffer comprises 10mM-100mM sodium chloride, 0.5mM-5mM potassium chloride, 0.1mM-5mM calcium chloride, 0.2mM-5mM magnesium sulfate, 5mM-300mM sodium bicarbonate, 0.1mM-35mM citric acid, 1mM-100mM sodium citrate, 0.5mM-150mM sodium acetate, 1mM-100mM glucose, 5mM-300mM trehalose and 0.1µg / ml-10µg / ml alprostadil; Centrifuging the pre-treated sample to obtain a second supernatant and a second precipitate, and resuspending the second precipitate with the lyophilization buffer to obtain a lyophilized solution; The lyophilized liquid is lyophilized to obtain the platelet lyophilized powder.
8. The preparation method according to claim 7, characterized in that: The freeze-drying comprises pre-freezing at -45°C to -35°C for 120min to 200min, then heating to -25°C to -15°C and maintaining for more than 1000min, and finally heating to 20°C to 35°C and maintaining for more than 360min.
9. The preparation method according to claim 5, characterized in that: The method for preparing the deproteinized serum matrix, the coagulation factor and the fibrinogen comprises: After anticoagulation, the blood was centrifuged and plasma was collected; The plasma is frozen, thawed, and then centrifuged to obtain a first supernatant and a first precipitate; the first precipitate is dissolved and then centrifuged to obtain an upper layer of liquid that is the fibrinogen; The first supernatant is subjected to protein precipitation, and a second supernatant and a second precipitate are obtained by centrifugation, wherein the second supernatant is the deproteinized serum matrix; The second precipitate is dissolved and placed in a dialysis bag for dialysis, and the liquid in the dialysis bag is then centrifuged and concentrated to obtain the coagulation factor.
10. Use of the inter-laboratory quality assessment sample according to any one of claims 1 to 4 or the inter-laboratory quality assessment sample prepared by the preparation method according to any one of claims 5 to 9 in the quality control of thromboelastography test reagents.
Citation Information
Cited By
Activated blood coagulation detection reagent whole blood quality control product and preparation method thereof
CN120522401A
